All Outputs (5)

High tissue inhibitor of matrix-metalloproteinase 2 expression correlates with poor prognosis in breast cancer (2020)
Presentation / Conference Contribution
Heyman, T., Joseph, C., Craze, M., Green, A., Nolan, C., Rueda, O., Provenzano, E., Rakha, E., Ellis, I. O., & Mukherjee, A. (2020, December). High tissue inhibitor of matrix-metalloproteinase 2 expression correlates with poor prognosis in breast cancer. Presented at 32nd Congress of the ESP and XXXIII International Congress of the IAP, Glasgow, UK (virtual)

Background & objectives
TIMP2, tissue inhibitor of matrix-metalloproteinase 2, inhibits the matrix-metalloproteinase, MMP2, but may activate pro-MMP2. Hence its correlation with prognosis in breast cancer (BC) is contradictory. This study investigat... Read More about High tissue inhibitor of matrix-metalloproteinase 2 expression correlates with poor prognosis in breast cancer.

Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer (2020)
Journal Article
Morotti, M., Zois, C. E., El-Ansari, R., Craze, M. L., Rakha, E. A., Fan, S.-J., Valli, A., Haider, S., Goberdhan, D. C. I., Green, A. R., & Harris, A. L. (2021). Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer. British Journal of Cancer, 124(2), 494-505. https://doi.org/10.1038/s41416-020-01113-y

PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer (2020)
Journal Article
Alfarsi, L. H., El Ansari, R., Craze, M. L., Masisi, B. K., Ellis, I. O., Rakha, E. A., & Green, A. R. (2020). PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer. BMC Cancer, 20(1), Article 425. https://doi.org/10.1186/s12885-020-06939-6

Background
PPFIA1 is an important regulator of cell migration and invasion, regulating focal adhesion signalling and disassembly. PPFIA1 is frequently amplified in breast cancer, and recent functional studies indicate that PPFIA1 is an important pro... Read More about PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer.

The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer (2020)
Journal Article
Ansari, R., Craze, M. L., Alfarsi, L., Masisi, B. K., Ellis, I. O., Rakha, E. A., & Green, A. R. (2020). The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer. Breast Cancer Research and Treatment, 181(1), 1-12. https://doi.org/10.1007/s10549-020-05586-6

Purpose: Breast cancer (BC) is a heterogeneous disease consisting of various subtypes, with
different prognostic and therapeutic outcomes. The amino acid transporter, SLC7A8, is over expressed in estrogen receptor positive BC. However the consequenc... Read More about The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer.

Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer (2020)
Journal Article
Alfarsi, L. H., El-Ansari, R., Craze, M. L., Masisi, B. K., Mohammed, O. J., Rakha, E. A., Ellis, I. O., & Green, A. R. (2020). Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer. International Journal of Molecular Sciences, 21(4), Article 1407. https://doi.org/10.3390/ijms21041407

The majority of breast cancers are oestrogen receptor positive (ER+) and are subject to endocrine therapy however, an unpredictable subgroup of patients will develop resistance to endocrine therapy. SLC7A5/SLC3A2 complex is a major route for the tran... Read More about Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer.